Tuesday, September 4, 2012

Eaton Scientific Enters Agreement with RoxSan Pharmacy to Provide Tropine 3 for its upcoming Clinical Trial Participants

Eaton Scientific Enters Agreement with RoxSan Pharmacy to Provide Tropine 3 for its upcoming Clinical Trial Participants

BEVERLY HILLS, Calif., Sept. 4, 2012 /PRNewswire/ -- Eaton Scientific Systems, Ltd. ("Eaton Scientific" or the "Company"), a wholly owned subsidiary of Pristine Solutions, Inc. (OTCQB: PRTN) is pleased to announce that the Company has entered into an agreement with RoxSan Pharmacy Inc. to provide continued specialized compound prescription of Homatropine in a novel oral suspension ("Tropine 3") to support planned FDA compliant Clinical trial participants.  Tropine 3 is a patent pending novel indication of an existing FDA approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, peri-menopausal, and post-menopausal women.  Details regarding the multi-location multi-phase FDA compliant Tropine 3 clinic trials are expected to be finalized within the next few weeks.

"We feel that the RoxSan Pharmacy team and facilities are uniquely qualified to continually supply the Clinical Trial with the highest-quality custom dosage of and support during our planned FDA compliant clinical trials period that is excepted to dramatically increase localized demand," stated Michael Borkowski, CEO and President of Eaton Scientific.

RoxSan Pharmacy has over 40 years of experience with a highly-qualified and educated team of pharmacists, technicians, and chemists to custom prepare high-quality compounded and manufactured medications using several unique delivery systems including, but not limited to, lozenges, nasal spray, cream, lotion, or transdermal gel.  RoxSan Pharmacy services are tilized by a variety of health care participants, including new drug developers, dermatologists, plastic surgeons, orthopedic surgeons, and pain care specialists.

Compounding pharmacies provide medications that are individually formulated to meet the patient's specific health care needs. Custom compounding formulations allows users to quickly and economically modify delivery form, create combination preparations, prescribed specific formulations, and dosage modifications.  Preparation of these specialized products requires chemicals, equipment, and skills that are not available in common pharmacies.

RoxSan Pharmacy is based in Beverly Hills, California and led by the acclaimed doctors Shana Melamed, Pharm.D and son Hootan Melamed, Pharm.D. RoxSan Pharmacy is a member of the Beverly Hills Chamber of Commerce, American Fertility Association, California Pharmacist Association, National Community Pharmacist Association, and the International Academy of Compounding Pharmacies.  Shana Melamed was previously named Beverly Hills Business Woman of The Year in three consecutive years. www.roxsan.com

About Pristine Solutions, Inc.

Pristine Solutions, Inc., through its wholly-owned subsidiary company, Eaton Scientific Systems, Ltd., holds the intellectual property and global marketing rights to Tropine 3, a patent pending novel indication of an existing FDA approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, pari-menopausal, and post-menopausal women.

Forward-Looking Statements/Disclaimer

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  The words "forecast", "anticipate","estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pristine Solutions' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pristine Solutions' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pristine Solutions herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pristine Solutions disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Eaton Scientific Systems, Ltd.

Back to top


Source: www.prnewswire.com

No comments:

Post a Comment